(Cross-reactive) antibody titers following two different seasonal influenza vaccines in a cohort of 14 HIV-infected patients.

Seroprotection- and seroconversion rates and geometric mean titers (GMT) to 2005–2006 seasonal influenza A(H1N1) virus, to 2009–2010 seasonal influenza A(H1N1) virus and to 2009 pandemic influenza A(H1N1) (pH1N1) virus for 14 HIV infected individuals following vaccination with seasonal trivalent inactivated influenza vaccine (TIV) in 2005 (A/New Caledonia/20/1999 (H1N1) like strain), with seasonal TIV in October 2009 (A/Brisbane/59/2007 (H1N1) like strain) and with a first dose of monovalent MF59-adjuvanted pH1N1 vaccine (A/California/7/2009) in November 2009.*Population characteristics in 2009: 86% male, median age 48 years (IQR 47–66), 86% on cART, median CD4+ T-lymphocytes 532 cells/mm3 (IQR 349–725), baseline HIV-1 RNA 71% 400 copy/ml. Population characteristics in 2005: 64% on cART, median CD4+ T-lymphocytes 473 cells/mm3 (IQR 285–752), baseline HIV-1 RNA 57% 400 copy/ml.